By John Gruber
WorkOS: APIs to ship SSO, SCIM, FGA, and User Management in minutes. Check out their launch week.
The New York Times:
A study in Israel showed that the vaccine is robustly effective after the first shot, echoing what other research has shown for the AstraZeneca vaccine and raising the possibility that regulators in some countries could authorize delaying a second dose instead of giving both on the strict schedule of three weeks apart as tested in clinical trials. […]
Published in The Lancet on Thursday and drawing from a group of 9,100 Israeli health care workers, the study showed that Pfizer’s vaccine was 85 percent effective 15 to 28 days after receiving the first dose. Pfizer and BioNTech’s late-stage clinical trials, which enrolled 44,000 people, showed that the vaccine was 95 percent effective if two doses were given three weeks apart. […]
Pfizer and BioNTech also announced on Friday that their vaccine can be stored at standard freezer temperatures for up to two weeks, potentially expanding the number of smaller pharmacies and doctors’ offices that could administer the vaccine, which now must be stored at ultracold temperatures.
The U.S. needs to change its policy and get more shots into more arms as quickly as possible. Administer the second booster shots in the summer after a majority of Americans have gotten their first. The current policy is simply wrong, given the data, and is halving the rate at which we can achieve herd immunity.
★ Friday, 19 February 2021